Original Investigation | Publication Year | First Author | # of weeks to first follow-up encounter, at least 3 months (at 12 weeks) since onset of semaglutide dose | Starting dose semaglutide | Estimated Mean Percent Weight Loss (%) at first follow-up encounter | Estimated Mean Percent Weight Loss (%) at second follow-up encounter (if applicable) | Percent Weight Loss (%) at third follow-up encounter (if applicable) | p-value reported |
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial | 2022 | Garvey | 12 | 2.4 mg | 5.90% | 12.20% | 15.20% | p < 0.0001 |
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. | 2022 | Ghusn | 12 | 1.7 mg | 5.70% | 10.90% | n/a | p < 0.001 |
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial | 2021 | Wadden | 68 | 2.4 mg | 16.00% | n/a | n/a | p < 0.001 |
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial | 2017 | Ahren | 56 | 1.0 mg | 5.50% | n/a | n/a | p < 0.0001 |
Average # of weeks to attain average percent weight loss |
|
| 37 |
| 8.28% | Average percent weight loss from the four original studies listed |
|
|